NEW YORK--(BUSINESS WIRE)--Onco360, one of the nation’s largest independent providers of Oncology Pharmacy services, today announced that it has been selected by Bayer AG (“Bayer”) as a limited distribution pharmacy network participant for two of its leading oncology medications, Nexavar® (sorafenib) and Stivarga® (regorafenib). With the addition of these two medications, Onco360’s industry-leading oncology medication portfolio now comprises nearly 40 limited distribution products.
Both of the new additions to Onco360’s portfolio have been approved by the U.S. Food and Drug Administration (FDA) as targeted therapies in comprehensive cancer treatment and are immediately available for order through Onco360.
Help employers find you! Check out all the jobs and post your resume.
